LXEO — Lexeo Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $401.25m
- $208.93m
Annual balance sheet for Lexeo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 136 | 77.3 | 121 | 122 | 182 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 137 | 80 | 124 | 126 | 188 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.174 | 13.8 | 12.3 | 10.6 | 8.86 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 137 | 97.1 | 140 | 147 | 269 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.45 | 14.3 | 17.2 | 22.8 | 16.8 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.45 | 25 | 26.3 | 30.1 | 22 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 129 | 72.1 | 114 | 117 | 247 |
| Total Liabilities & Shareholders' Equity | 137 | 97.1 | 140 | 147 | 269 |
| Total Common Shares Outstanding |